{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:26:15Z","timestamp":1783077975277,"version":"3.54.6"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To the best of our knowledge, no study so far has investigated the coasting effect of neuropathy caused by occupational exposure to\n                    <jats:italic>n<\/jats:italic>\n                    -hexane through more detailed clinical evaluations than nerve conduction measurements, such that would also include pain assessment and functional status. The aim of our study was therefore to see if our measurements, which include all three elements, would support the coasting effect and reveal associations between electrophysiological measurements and clinical symptom assessments over a 12-month follow-up. Our study included eighteen patients working in the same shoe factory who were diagnosed with occupational neuropathy most likely caused by exposure to\n                    <jats:italic>n<\/jats:italic>\n                    -hexane. After identification of occupational exposure to high, yet unspecified VOC levels by local health authorities, production was suspended and all patients removed from further exposure. All underwent detailed neurological examination, including electroneuromyography (EMG) and the assessment of self-rated pain severity, symptoms, and functionality in everyday activities. All clinical, laboratory, and electrophysiological assessments were performed at baseline and at months 4 and 12 of follow-up. The patients presented with different degrees of numbness, muscle weakness, and sensory disturbances. EMG measurements and clinical scales at month 4 revealed significant worsening from the baseline (p&lt;0.05), and the assessments at month 12 a significant improvement from month 4 (p&lt;0.05), which confirms the coasting effect. Significant correlations were found between baseline motor conduction velocities and subsequent functional outcomes, and between selected sensory parameters and pain severity. Regardless of its limitations, our study points to the real-life consequences of exposure to harmful VOCs in poorly controlled shoe factory environments and establishes the coasting effect through more than one diagnostic parameter. From a preventive perspective, our findings suggest that early electrophysiological evaluation, together with simple and validated clinical scales, may help identify workers at risk of developing neuropathy before irreversible functional impairments occur. Such an approach could inform timely exposure control, medical surveillance, and occupational interventions in high-risk settings.\n                  <\/jats:p>","DOI":"10.2478\/aiht-2026-77-4034","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:16:30Z","timestamp":1775456190000},"page":"28-38","source":"Crossref","is-referenced-by-count":0,"title":["Coasting effect of\n                    <i>n<\/i>\n                    -hexane-induced neuropathy evidenced by electroneuromyography and clinical symptom scales: a 12-month follow-up study"],"prefix":"10.2478","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5519-1196","authenticated-orcid":false,"given":"Yusuf","family":"Ko\u00e7ak","sequence":"first","affiliation":[{"name":"Tokat Gaziosmanpa\u015fa University Faculty of Medicine , Department of Neurology , Tokat , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"Kulu","sequence":"additional","affiliation":[{"name":"Tokat Gaziosmanpa\u015fa University Faculty of Medicine , Department of Neurology , Tokat , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba Demirer","family":"\u00c7eker","sequence":"additional","affiliation":[{"name":"Tokat Gaziosmanpa\u015fa University Faculty of Medicine , Department of Neurology , Tokat , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"S\u00fcmb\u00fcl","sequence":"additional","affiliation":[{"name":"Tokat Gaziosmanpa\u015fa University Faculty of Medicine , Department of Neurology , Tokat , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00fcrdane","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Tokat Gaziosmanpa\u015fa University Faculty of Medicine , Department of Neurology , Tokat , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bet\u00fcl","family":"\u00c7evik","sequence":"additional","affiliation":[{"name":"Tokat Gaziosmanpa\u015fa University Faculty of Medicine , Department of Neurology , Tokat , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_001","unstructured":"Y\u00fcksel G, Karl\u0131kaya G, Tutkavul K, Varl\u0131ba\u015f F, Y\u0131ld\u0131r\u0131m B, \u00d6rken C, Tireli H. Clinical and electrodiagnostic findings of n-hexane neuropathy. J Neurol Sci (Turkish) 2007;24:219\u201325."},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_002","doi-asserted-by":"crossref","unstructured":"Chaqda M, El Mellakh M, Kissani N, Louhab N. Neuropathy caused by addictive inhalation of n-hexane in glue sniffers. Presse Med 2019;48:568\u201372. doi: 10.1016\/j.lpm.2019.04.001","DOI":"10.1016\/j.lpm.2019.04.001"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_003","doi-asserted-by":"crossref","unstructured":"Valentine WM. Toxic peripheral neuropathies: agents and mechanisms. Toxicol Pathol 2020;48:152\u201373. doi: 10.1177\/0192623319854326","DOI":"10.1177\/0192623319854326"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_004","doi-asserted-by":"crossref","unstructured":"Guimaraes-Costa R, Schoindre Y, Metlaine A, Lefaucheur JP, Camdessanche JP, Maisonobe T, L\u00e9ger JM. N-hexane exposure: a cause of small fiber neuropathy. J Peripher Nerv Syst 2018;23:143\u20136. doi: 10.1111\/jns.12261","DOI":"10.1111\/jns.12261"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_005","doi-asserted-by":"crossref","unstructured":"Pastore C, Marhuenda D, Marti J, Cardona A. Early diagnosis of n-hexane-caused neuropathy. Muscle Nerve 1994;17:981\u20136. doi: 10.1002\/mus.880170904","DOI":"10.1002\/mus.880170904"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_006","doi-asserted-by":"crossref","unstructured":"Sendur OF, Turan Y, Bal S, Gurgan A. Toxic neuropathy due to n-hexane: report of three cases. Inhal Toxicol 2009;21:210\u20134. doi: 10.1080\/08958370802311169","DOI":"10.1080\/08958370802311169"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_007","doi-asserted-by":"crossref","unstructured":"Yamamura Y. n-hexane polyneuropathy. Folia Psychiatr Neurol Jpn 1969;23:45\u201357. doi: 10.1111\/j.1440-1819.1969.tb01441.x","DOI":"10.1111\/j.1440-1819.1969.tb01441.x"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_008","doi-asserted-by":"crossref","unstructured":"Huang CC, Chu NS, Cheng SY, Shin TS. Biphasic recovery in n-hexane polyneuropathy: A clinical and electrophysiological study. Acta Neurol Scand 1989;80:610\u20135. doi: 10.1111\/j.1600-0404.1989.tb03936.x","DOI":"10.1111\/j.1600-0404.1989.tb03936.x"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_009","unstructured":"Toxicological Profile for n-hexane. Atlanta (GA): Agency for Toxic Substances Disease Registry (ATSDR) U.S. Department of Health and Human Services; 2025."},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_010","doi-asserted-by":"crossref","unstructured":"G\u00f6z\u00fcbatik \u00c7elik RG, Toprak UE, K\u0131ran S. Neurotoxicological effects of environmental and occupational agents. Turk J Neurol 2022;28:63\u201372. doi: 10.4274\/tnd.2022.90023","DOI":"10.4274\/tnd.2022.90023"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_011","unstructured":"Hamilton RJ, Schaffer DH. n-hexane Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025."},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_012","doi-asserted-by":"crossref","unstructured":"Alpaydin Baslo S, Ozturk O, Dayan C, Atakli D, Baslo MB. Another brick in the wall: is hexane neuropathy a \u2018nodo-paranodopathy\u2019? Acta Neurol Belg 2021;121:373\u20138. doi: 10.1007\/s13760-019-01137-z","DOI":"10.1007\/s13760-019-01137-z"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_013","unstructured":"Berger AR, Schaumburg HH. Human toxic neuropathy caused by industrial agents. In: Dyck PJ, Thomas PK, editors. Peripheral Neuropathy. Vol. 2. 4th ed. Philadephia: Elsevier Saunders; 2005. p. 2505\u201325."},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_014","doi-asserted-by":"crossref","unstructured":"London Z, Albers JW. Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin 2007;25:257\u201376. doi: 10.1016\/j.ncl.2006.10.001","DOI":"10.1016\/j.ncl.2006.10.001"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_015","doi-asserted-by":"crossref","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE. PubChem 2025 update. Nucleic Acids Research. 2024;53(D1):D1516\u2013D25. doi: 10.1093\/nar\/gkae1059","DOI":"10.1093\/nar\/gkae1059"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_016","doi-asserted-by":"crossref","unstructured":"Mirian A, Aljohani Z, Grushka D, Florendo-Cumbermack A. Diagnosis and management of patients with polyneuropathy. CMAJ 2023;195(6):E227\u2013E33. doi: 10.1503\/cmaj.220936","DOI":"10.1503\/cmaj.220936"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_017","unstructured":"Preston DC, Shapiro BE. Polyneuropathy. In: Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations. 2nd ed. Philadelphia: Elsevier Butterworth-Heinemann; 2005. p. 389\u2013420."},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_018","doi-asserted-by":"crossref","unstructured":"Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005;14:798\u2013804. doi: 10.1111\/j.1365-2702.2005.01121.x","DOI":"10.1111\/j.1365-2702.2005.01121.x"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_019","doi-asserted-by":"crossref","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105\u201321. doi: 10.1016\/j.jpain.2007.09.005","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_020","doi-asserted-by":"crossref","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149\u201358. doi: 10.1016\/S0304-3959(01)00349-9","DOI":"10.1037\/t64335-000"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_021","doi-asserted-by":"crossref","unstructured":"Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 2005;6:149\u201358. doi: 10.1016\/j.jpain.2004.11.007.","DOI":"10.1016\/j.jpain.2004.11.007"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_022","doi-asserted-by":"crossref","unstructured":"Ko\u00e7 R, Erdemoglu KA. Validity and reliability of the Turkish Self-administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire. Pain Med 2010;11:1107\u201314. doi: 10.1111\/j.1526-4637.2010.00837.x","DOI":"10.1111\/j.1526-4637.2010.00837.x"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_023","doi-asserted-by":"crossref","unstructured":"T\u00fcrkel Y, T\u00fcrker H, Demir IA, Bayrak AO, Onar MK. Validation of self report version of the Leeds Assessment of Neuropathic Symptoms and Signs score for identification of neuropathic pain in patients from northern Turkey. Adv Clin Exp Med 2014;23:599\u2013603. doi: 10.17219\/acem\/37233","DOI":"10.17219\/acem\/37233"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_024","doi-asserted-by":"crossref","unstructured":"Kucukdeveci AA, Yavuzer G, Elhan AH, Sonel B, Tennant A. Adaptation of the functional independence measure for use in Turkey. Clin Rehabil 2001;15:311\u20139. doi: 10.1191\/026921501676877265","DOI":"10.1191\/026921501676877265"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_025","doi-asserted-by":"crossref","unstructured":"Beninato M, Gill-Body KM, Salles S, Stark PC, Black-Schaffer RM. Determination of the minimal clinically important difference in the FIM instrument in patients with stroke. Arch Phys Med Rehabil 2006;87:32\u20139. doi: 10.1016\/j.apmr.2005.08.130","DOI":"10.1016\/j.apmr.2005.08.130"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_026","unstructured":"Garc\u00eda-Rudolph A, Wright M, Garc\u00eda L, Sauri J, Cegarra B, Tormos JM, Opisso E. Long-term prediction of functional independence using adjusted and unadjusted single items of the functional independence measure (FIM) at discharge from rehabilitation. J Spinal Cord Med 2024;47:649\u201360. oi: 10.1080\/10790268.2023.2183326"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_027","doi-asserted-by":"crossref","unstructured":"Heinemann AW, Linacre JM, Wright BD, Hamilton BB, Granger CV. Relationships between impairment and physical disability as measured by the functional independence measure. Arch Phys Med Rehabil 1993;74:566\u201373. doi: 10.1016\/0003-9993(93)90153-2","DOI":"10.1016\/0003-9993(93)90153-2"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_028","doi-asserted-by":"crossref","unstructured":"Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006;77:973\u20136. doi: 10.1136\/jnnp.2005.081547","DOI":"10.1136\/jnnp.2005.081547"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_029","doi-asserted-by":"crossref","unstructured":"van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011;76:337\u201345. doi: 10.1212\/WNL.0b013e318208824b","DOI":"10.1212\/WNL.0b013e318208824b"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_030","doi-asserted-by":"crossref","unstructured":"Rajabally YA, Nazeer KK, Min YG. Minimal clinically important differences in measuring treatment effects in CIDP: history, current use, limitations, and prospects. Muscle Nerve 2025;72:1042\u201351. doi: 10.1002\/mus.28478","DOI":"10.1002\/mus.28478"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_031","doi-asserted-by":"crossref","unstructured":"Merkies ISJ, Schmitz PIM, van der Mech\u00e9 FGA, Samijn JPA, van Doorn PA. Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596\u2013601. doi: 10.1136\/jnnp.72.5.596","DOI":"10.1136\/jnnp.72.5.596"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_032","doi-asserted-by":"crossref","unstructured":"Chang AP, England JD, Garcia CA, Sumner AJ. Focal conduction block in n-hexane polyneuropathy. Muscle Nerve 1998;21:964\u20139. doi: \n10.1002\/(sici)1097-4598(199807)21:7<964::aid-mus21>3.0.co;2-p","DOI":"10.1002\/(SICI)1097-4598(199807)21:7<964::AID-MUS21>3.3.CO;2-I"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_033","doi-asserted-by":"crossref","unstructured":"Singh G, Chopra JS. An appraisal of the role of clinical neurophysiology in toxic neuropathy. Suppl Clin Neurophysiol 2002;54:97\u2013104. doi: 10.1016\/S1567-424X(09)70433-7","DOI":"10.1016\/S1567-424X(09)70433-7"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_034","doi-asserted-by":"crossref","unstructured":"Peters J, Staff NP. Update on toxic neuropathies. Curr Treat Options Neurol 2022;24:203\u201316. doi: 10.1007\/s11940-022-00716-5","DOI":"10.1007\/s11940-022-00716-5"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_035","doi-asserted-by":"crossref","unstructured":"Rerger AR, Schaumburg HH, Schroeder C, Apfel S, Reynolds H. Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity. Neurology 1992;42:1367\u201370. doi: 10.1212\/wnl.42.7.1367","DOI":"10.1212\/WNL.42.7.1367"},{"key":"2026070310595241945_j_aiht-2026-77-4034_ref_036","doi-asserted-by":"crossref","unstructured":"Yuki EFN, Soares R, Kupa LVK, Heise CO, Aikawa NE, Arnone M, Romiti R, Pedrosa TDN, Silva CAAD, Bonfa E, Pasoto SG. One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. Lupus 2021;30:956\u201364. doi: 10.1177\/0961203321998433","DOI":"10.1177\/0961203321998433"}],"container-title":["Archives of Industrial Hygiene and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/aiht-2026-77-4034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:01:48Z","timestamp":1783076508000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/aiht-2026-77-4034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/aiht-2026-77-4034"],"URL":"https:\/\/doi.org\/10.2478\/aiht-2026-77-4034","relation":{},"ISSN":["1848-6312"],"issn-type":[{"value":"1848-6312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}